Evidence map›Paper›PMID 42272952›Full record

ArticleBioengineering & translational medicine2026

PEGylation strategies for enhanced nanoparticle delivery to tumor-associated immune cells.

Devorah Cahn, Sanjay Pal, Alexa Stern, Nimit L Patel, Timothy Gower, Senta M Kapnick, Christopher M Jewell, Gregg A Duncan, Matthew T Wolf

Abstract read
In one paragraph

Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Devorah CahnCancer Biomaterials Engineering Section, Cancer Innovation Laboratory, Center for Cancer Research National Cancer Institute Frederick Maryland USA.
Sanjay PalCancer Biomaterials Engineering Section, Cancer Innovation Laboratory, Center for Cancer Research National Cancer Institute Frederick Maryland USA.
Alexa SternFischell Department of Bioengineering University of Maryland College Park Maryland USA.
Nimit L PatelSmall Animal Imaging Program, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research Frederick Maryland USA.
Timothy GowerSmall Animal Imaging Program, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research Frederick Maryland USA.
Senta M KapnickFischell Institute of Biomedical Devices University of Maryland College Park Maryland USA.
Christopher M JewellFischell Institute of Biomedical Devices University of Maryland College Park Maryland USA.
Gregg A DuncanFischell Department of Bioengineering University of Maryland College Park Maryland USA.
Matthew T WolfCancer Biomaterials Engineering Section, Cancer Innovation Laboratory, Center for Cancer Research National Cancer Institute Frederick Maryland USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barriers to nanoparticle drug delivery to the tumor microenvironment such as ECM deposition and clearance by the mononuclear phagocyte system have necessitated strategies for more effective tumor penetration. Adding polyethylene glycol (PEG) chains to the surface of nanoparticles (PEGylation) has been widely used to both enhance accumulation at the tumor site and increase blood circulation time. Recent work has also shown that immune cells (e.g., macrophages, dendritic cells, neutrophils) play an important role in the ability of NPs to effectively target and spread within a tumor. PEG chain characteristics such as size and branching affect how nanoparticles interact with tissues; however, it is unclear how PEGylation type affects NP uptake and cellular distribution in the tumor microenvironment. In this study, we evaluated the influence of both linear and branched PEGylation on nanoparticle biodistribution and uptake in tumor cells as well as tumor-infiltrating immune cells. As compared to conventional surface coatings with linear PEG, we show that modifying PEG structure to a branched conformation increases nanoparticle accumulation in the spleen of tumor-bearing mice, primarily due to significantly enhanced uptake by leukocytes. As compared to uncoated particles, we also found that nanoparticles densely coated with linear or branched PEG accumulated to a greater extent in tumors showing ≥8-fold increases in uptake by tumor-associated macrophages and dendritic cells. These studies provide insight into PEG architecture as a design parameter in nanomedicine that can facilitate the design of more effective cancer therapies.

Indexed as

cancerdrug deliverynanoparticlesPEGylationphagocytes

Identifiers

PMID42272952
PMCPMC13247401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.